Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218653 · ClinicalTrials.gov registry record · Early Phase 1
Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
NCT07218653: Clinical Trial Early Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT07218653 is a Early Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 72 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218653, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.
Primary Outcome
Data collected via MRI under one of 2 conditions: placebo or indomethacin.
Interventions
- DRUG Placebo
- DRUG Indomethacin
- DIAGNOSTIC_TEST MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-07 |
| Phase | Early Phase 1 |
What is known before NCT07218653 opens enrollment
NCT07218653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07218653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07218653 about?
NCT07218653 is a clinical study titled "Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome". This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.
What is the current status of trial NCT07218653?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2026-07. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07218653?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG), MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07218653?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07218653's enrollment target sits among peer trials
72 319th of 2000 higher than 1,673 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia